Acquired and specific immunological mechanisms co-responsible for efficacy of polymer-bound drugs
- 17 January 2002
- journal article
- Published by Elsevier in Journal of Controlled Release
- Vol. 78 (1-3) , 97-114
- https://doi.org/10.1016/s0168-3659(01)00489-8
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- ABNORMAL DIFFERENTIATION OF THYMOCYTES INDUCED BY FREE CYCLOSPORINE IS AVOIDED WHEN CYCLOSPORINE BOUND TO N-(2-HYDROXYPROPYL) METHACRYLAMIDE COPOLYMER CARRIER IS USED1Transplantation, 1997
- Arousal and inhibition of human NK cellsImmunological Reviews, 1997
- The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A proteinImmunology Today, 1994
- Immunomodulation by Antibacterial AgentsDrugs, 1993
- Drug-polymer conjugatesAnti-Cancer Drugs, 1992
- Antibody-targeted cyclosporin AJournal of Controlled Release, 1992
- Immunogenicity of Protein-N-(2-Hydroxypropyl)methacrylamide Copolymer Conjugates in A/J and B10 MiceJournal of Bioactive and Compatible Polymers, 1990
- Action of polymeric prodrugs based on N-(2-hydroxypropyl)-methacrylamide copolymers. II. Body distribution and T-cell accumulation of free and polymer-bound [125i]daunomycinJournal of Controlled Release, 1989
- Antibody-directed affinity therapy applied to the immune system: In vivo effectiveness and limited toxicity of daunomycin conjugated to HPMA copolymers and targeting antibodyClinical Immunology and Immunopathology, 1988
- ESTABLISHMENT AND CHARACTERIZATION OF PERMANENT MURINE HYBRIDOMAS SECRETING MONOCLONAL ANTI‐THY‐1 ANTIBODIES *International Journal of Immunogenetics, 1980